552 related articles for article (PubMed ID: 17375557)
1. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Bishnoi M; Kumar A; Chopra K; Kulkarni SK
Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):211-6. PubMed ID: 17520104
[TBL] [Abstract][Full Text] [Related]
3. In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration.
Kulkarni SK; Bishnoi M; Chopra K
Indian J Exp Biol; 2009 Feb; 47(2):91-7. PubMed ID: 19374163
[TBL] [Abstract][Full Text] [Related]
4. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
6. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
[TBL] [Abstract][Full Text] [Related]
8. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
Haleem DJ; Batool F; Khan NH; Kamil N; Ali O; Saify ZS; Haleem MA
Med Sci Monit; 2002 Sep; 8(9):BR354-61. PubMed ID: 12218936
[TBL] [Abstract][Full Text] [Related]
9. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
[TBL] [Abstract][Full Text] [Related]
10. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacology; 2007; 79(3):171-83. PubMed ID: 17377417
[TBL] [Abstract][Full Text] [Related]
12. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
13. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
[TBL] [Abstract][Full Text] [Related]
14. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
[TBL] [Abstract][Full Text] [Related]
15. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
[TBL] [Abstract][Full Text] [Related]
16. [A study on the pharmacological properties of atypical antipsychotic drugs: in vivo dopamine and serotonin receptor occupancy by atypical antipsychotic drugs in the rat brain].
Matsubara R
Hokkaido Igaku Zasshi; 1993 Jul; 68(4):570-82. PubMed ID: 7687976
[TBL] [Abstract][Full Text] [Related]
17. [Utility of quetiapine in tardive dyskinesia].
Navarro Pacheco BV; Montejo González AL; Martín Carrasco M
Actas Esp Psiquiatr; 2003; 31(6):347-52. PubMed ID: 14639511
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain.
O'Dell SJ; La Hoste GJ; Widmark CB; Shapiro RM; Potkin SG; Marshall JF
Synapse; 1990; 6(2):146-53. PubMed ID: 2237777
[TBL] [Abstract][Full Text] [Related]
19. Iron modulates neuroleptic-induced effects related to the dopaminergic system.
Ben-Shachar D; Livne E; Spanier I; Zuk R; Youdim MB
Isr J Med Sci; 1993 Sep; 29(9):587-92. PubMed ID: 7901181
[TBL] [Abstract][Full Text] [Related]
20. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.
Naidu PS; Singh A; Kulkarni SK
Br J Pharmacol; 2002 May; 136(2):193-200. PubMed ID: 12010767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
